Table 3 |
|||||||||||||
|
PRO response by clinical response* at week 52 (CZP 200 mg plus MTX group, ITT population) |
|||||||||||||
|
ACR20 response by (%) |
|||||||||||||
|
|
|||||||||||||
|
SF-36 PCS |
SF-36 MCS |
HAQ-DI |
Pain |
FAS |
PtGA |
||||||||
|
|
|||||||||||||
|
Clinical response |
No |
Yes |
No |
Yes |
No |
Yes |
No |
Yes |
No |
Yes |
No |
Yes |
|
|
PRO response |
No |
45.5 |
14.7 |
43.4 |
19.5 |
44.4 |
8.7 |
44.4 |
3.8 |
44.1 |
7.1 |
86.9 |
2.0 |
|
Yes |
1.0 |
38.8 |
3.1 |
33.9 |
2.6 |
44.4 |
1.0 |
38.2 |
2.8 |
45.9 |
0 |
11.1 |
|
|
Tetrachoric correlation (ASE) |
0.9450 (0.0178) |
0.8389 (0.0356) |
0.9504 (0.0152) |
0.9804 (0.0076) |
0.9574 (0.0135) |
0.9996 (0.0053) |
|||||||
|
DAS response by (%) |
|||||||||||||
|
|
|||||||||||||
|
SF-36 PCS |
SF-36 MCS |
HAQ-DI |
Pain |
FAS |
PtGA |
||||||||
|
|
|||||||||||||
|
Clinical response |
No |
Yes |
No |
Yes |
No |
Yes |
No |
Yes |
No |
Yes |
No |
Yes |
|
|
PRO response |
No |
44.2 |
16.5 |
43.2 |
20.4 |
43.6 |
10.0 |
43.6 |
5.1 |
43.9 |
7.7 |
44.1 |
4.9 |
|
Yes |
1.0 |
38.2 |
2.1 |
34.4 |
2.1 |
44.4 |
2.1 |
49.2 |
1.8 |
46.7 |
1.5 |
49.5 |
|
|
Tetrachoric correlation (ASE) |
0.9344 (0.0204) |
0.8674 (0.0322) |
0.9496 (0.0156) |
0.9776 (0.0085) |
0.9672 (0.0114) |
0.9833 (0.0069) |
|||||||
|
|
|||||||||||||
|
*Clinical response = DAS or ACR20 response. ACR20 = American College of Rheumatology 20% improvement; ASE = asymptomatic standard error; CZP = certolizumab pegol; DAS = disease activity score; FAS = fatigue assessment scale; HAQ-DI = health assessment questionnaire-disability index; ITT = intent to treat; MCS = mental component summary; MTX = methotrexate; PtGA = patient's global assessment; PCS = physical component summary; PRO = patient-reported outcomes; SF-36 = short-form 36-item health survey |
|||||||||||||
|
Strand et al. Arthritis Research & Therapy 2009 11:R170 doi:10.1186/ar2859 |
|||||||||||||
